{"id":46530,"date":"2022-08-31T12:11:10","date_gmt":"2022-08-31T12:11:10","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=97301"},"modified":"2022-08-31T12:11:10","modified_gmt":"2022-08-31T12:11:10","slug":"novo-estudo-publicado-no-clinical-cancer-research-journal-destaca-o-uso-do-teste-endopredict-para-informar-o-tratamento-em-pacientes-com-cancer-de-mama-na-pre-menopausa","status":"publish","type":"post","link":"https:\/\/southafricahorizon.com\/novo-estudo-publicado-no-clinical-cancer-research-journal-destaca-o-uso-do-teste-endopredict-para-informar-o-tratamento-em-pacientes-com-cancer-de-mama-na-pre-menopausa\/","title":{"rendered":"Novo estudo publicado no Clinical Cancer Research Journal destaca o uso do teste EndoPredict para informar o tratamento em pacientes com c\u00e2ncer de mama na pr\u00e9-menopausa"},"content":{"rendered":"<div>\n<ul>\n<li>O teste EndoPredict, da Myriad Genetics, identificou com precis\u00e3o mulheres na pr\u00e9-menopausa com c\u00e2ncer de mama ER+, HER2- que poderiam evitar, com seguran\u00e7a, a quimioterapia adjuvante<\/li>\n<\/ul>\n<p>SALT LAKE CITY, Aug. 31, 2022 (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3DjYyUyX0enLeKuoQMzcqHGbhQGmApEuG8X6QmwNQkPgEY10h9Po-u0sG9NKA52C8ungGm6NgmpkJMllx5UvIOH0cD2exT8B9jV2_HH7_-kEw%3D&amp;source=gmail-html&amp;ust=1662034242702000&amp;usg=AOvVaw1SZkpBDDxnU9Pij8AK9eXa\"  rel=\"nofollow noopener noreferrer\">A Myriad Genetics, Inc. <\/a>\u00a0(NASDAQ: MYGN), l\u00edder em testes gen\u00e9ticos e medicina de precis\u00e3o, anunciou hoje que o Clinical Cancer Research Journal<sup>1 <\/sup>publicou um <a href=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3Dlc6kTmYn0IFysPazqvJKJr4WyW7BnGzJQzSRhVgTrGuLA8xluBSlQbFePIxOPwp0fV2RGTVFbUeI-kB7XCR8wBxOi8gsafuSPP5o404tP963slJxgR5ply1D1PjqKmokCCztl0vrNDysELD-R1LskolJThqkn117koqBcNkHB8v-UAdPCTXB_yPqwLnGvhBgLxU0dskWfYn68CJXYADwug%3D%3D&amp;source=gmail-html&amp;ust=1662034242702000&amp;usg=AOvVaw2oz03lnBaWRpi0iwEKlw-W\"  rel=\"nofollow noopener noreferrer\">estudo<\/a> que mostra que o teste de progn\u00f3stico para c\u00e2ncer de mama EndoPredict<sup>\u00ae <\/sup>previu significativamente a recorr\u00eancia tardia em mulheres com c\u00e2ncer de mama em est\u00e1gio inicial, na pr\u00e9-menopausa, com ER+, HER2-. Este estudo, rec\u00e9m-publicado, representa a primeira valida\u00e7\u00e3o cl\u00ednica do EndoPredict em uma popula\u00e7\u00e3o, exclusivamente, na pr\u00e9-menopausa.<\/p>\n<p>O estudo \u2013 apresentado pela primeira vez como um <a href=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3DdMRBx2XdTy4iGW2sKI0y5tfkGL1qcAOFHMt4VAUV5BRAwcdpK00am3dn6mtEfqFulAmEiPaz26rJvNKZbzahN_ZVTOYASe2HMw1Ji4gcoECT7oZHICB-89R7aUN9i_Jo&amp;source=gmail-html&amp;ust=1662034242702000&amp;usg=AOvVaw0l9mh8RzOgygNt6Torr-2a\"  rel=\"nofollow noopener noreferrer\">resumo <\/a>na Reuni\u00e3o Anual da ASCO 2021 por Anastasia Constantinidou et al<sup>2 <\/sup>\u2013 examinou amostras de tumor de 385 mulheres na pr\u00e9-menopausa, com c\u00e2ncer de mama prim\u00e1rio, ER+ e HER2- que n\u00e3o receberam quimioterapia. Os resultados mostram que o EndoPredict identificou com precis\u00e3o mulheres na pr\u00e9-menopausa com e sem linfonodos comprometidos que poderiam evitar com seguran\u00e7a a quimioterapia adjuvante, como parte de seu plano de tratamento, devido a um risco de recorr\u00eancia muito baixo.<\/p>\n<p>\u201cEsta importante publica\u00e7\u00e3o, sobre os novos dados do EndoPredict, demonstra nosso compromisso cont\u00ednuo com o avan\u00e7o da medicina de precis\u00e3o para pacientes com c\u00e2ncer de mama\u201d, disse o Dr. Ralf Kronenwett, diretor de Assuntos M\u00e9dicos Internacionais da Myriad Genetics. \u201c\u00c0 luz das recomenda\u00e7\u00f5es cl\u00ednicas crescentes para reduzir o tratamento excessivo no c\u00e2ncer de mama, os resultados s\u00e3o particularmente encorajadores. Com cerca de um ter\u00e7o de todos os novos casos de c\u00e2ncer de mama ocorrendo em pacientes com 54 anos ou menos<sup>3 <\/sup>, o uso do EndoPredict entre mulheres na pr\u00e9-menopausa fornece informa\u00e7\u00f5es importantes para orientar o tratamento personalizado, incluindo se h\u00e1 benef\u00edcios em usar quimioterapia ou n\u00e3o.\u201d<\/p>\n<p>O estudo mostra que as pacientes com escores de baixo risco do EndoPredict tiveram uma sobrevida livre de recorr\u00eancia (DRFS) de 97% versus 76% para pacientes de alto risco. \u00c9 importante ressaltar que 19% das pacientes pr\u00e9-menop\u00e1usicas com linfonodo positivo tiveram escores de baixo risco EndoPredict com DRFS de 100% e que poderiam evitar a quimioterapia com seguran\u00e7a e continuar apenas com a terapia end\u00f3crina.<\/p>\n<p>Outro resultado importante de uma an\u00e1lise explorat\u00f3ria de subgrupo, dentro do estudo, encontrou taxas semelhantes de DRFS em pacientes de baixo risco com ou sem supress\u00e3o da fun\u00e7\u00e3o ovariana (OFS), com menos de 5% de recorr\u00eancia \u00e0 dist\u00e2ncia ap\u00f3s 10 anos, em ambos os grupos.<\/p>\n<p>&#8220;Este importante estudo mostra que as pacientes na pr\u00e9-menopausa com uma pontua\u00e7\u00e3o EPclin de baixo risco t\u00eam um bom resultado a longo prazo, sem quimioterapia, e podem ser consideradas para tratamento apenas com terapia end\u00f3crina&#8221;, disse a Dra. Anastasia Constantinidou, do \u201cBank of Cyprus Oncology Centre\u201d e do \u201cCyprus Cancer Research Institute\u201d. \u201cEssas descobertas s\u00e3o relevantes para orientar melhor as decis\u00f5es de tratamento personalizado para uma grande propor\u00e7\u00e3o de mulheres na pr\u00e9-menopausa com c\u00e2ncer de mama ER+, HER2- em est\u00e1gio inicial.\u201d<\/p>\n<p><strong>Sobre o estudo<\/strong><br \/>\nO EndoPredict \u00e9 um teste progn\u00f3stico que prev\u00ea o risco de recorr\u00eancia do c\u00e2ncer de mama para ajudar a identificar quem pode considerar abandonar a quimioterapia com seguran\u00e7a. Ele analisa 12 genes para criar uma pontua\u00e7\u00e3o molecular, que \u00e9 combinada com caracter\u00edsticas do tumor, como tamanho do tumor e status nodal, para estabelecer uma pontua\u00e7\u00e3o de risco da paciente (EPclin).<\/p>\n<p>O estudo \u201cClinical Validation of EndoPredict in Pre-Menopausal Women\u201d testou amostras de tumores de 385 mulheres na pr\u00e9-menopausa com c\u00e2ncer de mama prim\u00e1rio ER+, HER2- (pT1-3, pN0-1) que n\u00e3o receberam quimioterapia al\u00e9m da terapia end\u00f3crina. Todas as amostras foram testadas retrospectivamente, cegas para dados cl\u00ednicos e de resultados com EndoPredict. Associa\u00e7\u00f5es de escores de risco EPclin com sobrevida livre de recorr\u00eancia em 10 anos (DRFS) foram avaliadas por modelos de riscos proporcionais de Cox e an\u00e1lise de Kaplan-Meier. O desfecho prim\u00e1rio foi DRFS em 10 anos.<\/p>\n<p>Al\u00e9m de EPclin, as vari\u00e1veis cl\u00ednicas de interesse inclu\u00edram idade ao diagn\u00f3stico, tamanho do tumor, grau do tumor, estado nodal, express\u00e3o de Ki 67, express\u00e3o cont\u00ednua de receptor de estrog\u00eanio (ER) e express\u00e3o de receptor de progesterona (PgR).<\/p>\n<p>Mais informa\u00e7\u00f5es sobre este estudo podem ser encontradas <a href=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3DM74Q4rcKeHdTCRwl7hLRfjTuYU4ODPmbLCcv9ejKihavmCH9jR_xYB4Io6Ahj7FrBqXoq5y4PPS--5B4KKHlJ9-LhGPoOoCfbNqwPUyBJkJi1bf9A_8YXSY-ItR027diGs3HB-v94MdnUGm7hY58ISrs6nSfxz_b4P_u5C4IgL_Q0gl6eYUshrqxV0kXnn6X4w1hoe6daHqGsyMkNf8guA%3D%3D&amp;source=gmail-html&amp;ust=1662034242702000&amp;usg=AOvVaw2auUjaNllrinM8Bu7QelZv\"  rel=\"nofollow noopener noreferrer\">aqui<\/a>.<\/p>\n<p><sup>1 <\/sup>Constantinidou et al. Clin Cancer Res 2022; published online ahead of print<br \/>\n<sup>2 <\/sup>Constantinidou et al 2021 ASCO (<a href=\"https:\/\/www.google.com\/url?q=https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2021.39.15_suppl.537&amp;source=gmail-html&amp;ust=1662034242702000&amp;usg=AOvVaw1a-BYIN8jMFonkgdPzTMn9\"  rel=\"noopener noreferrer\">https:\/\/ascopubs.org\/doi\/abs\/<wbr \/>10.1200\/JCO.2021.39.15_suppl.<wbr \/>537<\/a>)<br \/>\n<sup>3<\/sup> SEER Cancer Statistics Review, 1975-2016. Bethesda, MD: Instituto Nacional do C\u00e2ncer; 2019.<\/p>\n<p><strong>Sobre a Myriad Genetics<\/strong><br \/>\nA Myriad Genetics \u00e9 uma empresa l\u00edder em testes gen\u00e9ticos e medicina de precis\u00e3o, dedicada a promover a sa\u00fade e o bem-estar de todos. A Myriad desenvolve e oferece testes gen\u00e9ticos que ajudam a avaliar o risco de desenvolver doen\u00e7as ou progress\u00e3o da doen\u00e7a e orientar as decis\u00f5es de tratamento em todas as especialidades m\u00e9dicas, onde as informa\u00e7\u00f5es gen\u00e9ticas podem melhorar significativamente o atendimento ao paciente e reduzir os custos de sa\u00fade. A Fast Company nomeou a Myriad entre as <em>empresas mais inovadoras do mundo para <\/em>2022. Para obter mais informa\u00e7\u00f5es, visite <a href=\"https:\/\/www.google.com\/url?q=https:\/\/www.globenewswire.com\/Tracker?data%3DgnVEsx8L8sXxz0bkpQ20hSA8IwKocQFZVhLyZAGVsKulW3pyDHsuah5p6RAgbO3KGUJAaDLRkquQ-A8LUwNEIzOnLAHCppBpF2kDEnXrkaG1D6C8k-4JeBikbzgwf69smvV6gLgHWqTOAi6qjVyhqTI3OCLms7lShVqIgbF5y0ejimTVdSslq3OTFozQa7AOBENW1-aU1kv2c--r85iHDppHW6JLpHKwICfbpVldMyA%3D&amp;source=gmail-html&amp;ust=1662034242702000&amp;usg=AOvVaw2qyLBDC4o4BnUDMVsYQYFw\"  rel=\"nofollow noopener noreferrer\">www.myriad.com<\/a>.<\/p>\n<p>Myriad, o logotipo da Myriad, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, Health.Illuminated., RiskScore, Prolaris , GeneSight e EndoPredict s\u00e3o marcas comerciais ou marcas registradas da Myriad Genetics, Inc. \u00a9 2022 Myriad Genetics, Inc. Todos os direitos reservados.<\/p>\n<p><strong>Safe Harbor Statement<\/strong><br \/>\nThis press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to using EndoPredict among premenopausal women to provide important insights to inform personalized treatment, including whether there\u2019s a benefit to using chemotherapy or not. These \u201cforward-looking statements\u201d are management\u2019s expectations of future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company\u2019s filings with the U.S. Securities and Exchange Commission, including the company\u2019s Annual Report on Form 10-K filed on February 25, 2022, as well as any updates to those risk factors filed from time to time in the company\u2019s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.<\/p>\n<table>\n<tbody>\n<tr>\n<td><strong>Media Contact:<\/strong><br \/>\nMegan Manzari<br \/>\n(385) 318-3718<br \/>\n<a href=\"mailto:Megan.Manzari@myriad.com\"  rel=\"noopener noreferrer\">Megan.Manzari@myriad.com<\/a><\/td>\n<td><\/td>\n<td><strong>Investor Contact: <\/strong><br \/>\nFoster Harris<br \/>\n(385) 350-8015<br \/>\n<a href=\"mailto:Foster.Harris@myriad.com\"  rel=\"noopener noreferrer\">Foster.Harris@myriad.com<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>O teste EndoPredict, da Myriad Genetics, identificou com precis\u00e3o mulheres na pr\u00e9-menopausa com c\u00e2ncer de mama ER+, HER2- que poderiam evitar, com seguran\u00e7a, a quimioterapia adjuvante SALT LAKE CITY, Aug. 31, 2022 (GLOBE NEWSWIRE) \u2014 A Myriad Genetics, Inc. \u00a0(NASDAQ: MYGN), l\u00edder em testes gen\u00e9ticos e medicina de precis\u00e3o, anunciou hoje que o Clinical Cancer [\u2026]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[30],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novo estudo publicado no Clinical Cancer Research Journal destaca o uso do teste EndoPredict para informar o tratamento em pacientes com c\u00e2ncer de mama na pr\u00e9-menopausa - South Africa Horizon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/southafricahorizon.com\/novo-estudo-publicado-no-clinical-cancer-research-journal-destaca-o-uso-do-teste-endopredict-para-informar-o-tratamento-em-pacientes-com-cancer-de-mama-na-pre-menopausa\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo estudo publicado no Clinical Cancer Research Journal destaca o uso do teste EndoPredict para informar o tratamento em pacientes com c\u00e2ncer de mama na pr\u00e9-menopausa - South Africa Horizon\" \/>\n<meta property=\"og:description\" content=\"O teste EndoPredict, da Myriad Genetics, identificou com precis\u00e3o mulheres na pr\u00e9-menopausa com c\u00e2ncer de mama ER+, HER2- que poderiam evitar, com seguran\u00e7a, a quimioterapia adjuvante SALT LAKE CITY, Aug. 31, 2022 (GLOBE NEWSWIRE) \u2014 A Myriad Genetics, Inc. \u00a0(NASDAQ: MYGN), l\u00edder em testes gen\u00e9ticos e medicina de precis\u00e3o, anunciou hoje que o Clinical Cancer [\u2026]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/southafricahorizon.com\/novo-estudo-publicado-no-clinical-cancer-research-journal-destaca-o-uso-do-teste-endopredict-para-informar-o-tratamento-em-pacientes-com-cancer-de-mama-na-pre-menopausa\/\" \/>\n<meta property=\"og:site_name\" content=\"South Africa Horizon\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-31T12:11:10+00:00\" \/>\n<meta name=\"author\" content=\"shadmin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"shadmin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/southafricahorizon.com\/novo-estudo-publicado-no-clinical-cancer-research-journal-destaca-o-uso-do-teste-endopredict-para-informar-o-tratamento-em-pacientes-com-cancer-de-mama-na-pre-menopausa\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/southafricahorizon.com\/novo-estudo-publicado-no-clinical-cancer-research-journal-destaca-o-uso-do-teste-endopredict-para-informar-o-tratamento-em-pacientes-com-cancer-de-mama-na-pre-menopausa\/\"},\"author\":{\"name\":\"shadmin\",\"@id\":\"https:\/\/southafricahorizon.com\/#\/schema\/person\/fdceae9c738422cfffedeec2ab0f5fdd\"},\"headline\":\"Novo estudo publicado no Clinical Cancer Research Journal destaca o uso do teste EndoPredict para informar o tratamento em pacientes com c\u00e2ncer de mama na pr\u00e9-menopausa\",\"datePublished\":\"2022-08-31T12:11:10+00:00\",\"dateModified\":\"2022-08-31T12:11:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/southafricahorizon.com\/novo-estudo-publicado-no-clinical-cancer-research-journal-destaca-o-uso-do-teste-endopredict-para-informar-o-tratamento-em-pacientes-com-cancer-de-mama-na-pre-menopausa\/\"},\"wordCount\":1155,\"publisher\":{\"@id\":\"https:\/\/southafricahorizon.com\/#organization\"},\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/southafricahorizon.com\/novo-estudo-publicado-no-clinical-cancer-research-journal-destaca-o-uso-do-teste-endopredict-para-informar-o-tratamento-em-pacientes-com-cancer-de-mama-na-pre-menopausa\/\",\"url\":\"https:\/\/southafricahorizon.com\/novo-estudo-publicado-no-clinical-cancer-research-journal-destaca-o-uso-do-teste-endopredict-para-informar-o-tratamento-em-pacientes-com-cancer-de-mama-na-pre-menopausa\/\",\"name\":\"Novo estudo publicado no Clinical Cancer Research Journal destaca o uso do teste EndoPredict para informar o tratamento em pacientes com c\u00e2ncer de mama na pr\u00e9-menopausa - South Africa Horizon\",\"isPartOf\":{\"@id\":\"https:\/\/southafricahorizon.com\/#website\"},\"datePublished\":\"2022-08-31T12:11:10+00:00\",\"dateModified\":\"2022-08-31T12:11:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/southafricahorizon.com\/novo-estudo-publicado-no-clinical-cancer-research-journal-destaca-o-uso-do-teste-endopredict-para-informar-o-tratamento-em-pacientes-com-cancer-de-mama-na-pre-menopausa\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/southafricahorizon.com\/novo-estudo-publicado-no-clinical-cancer-research-journal-destaca-o-uso-do-teste-endopredict-para-informar-o-tratamento-em-pacientes-com-cancer-de-mama-na-pre-menopausa\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/southafricahorizon.com\/novo-estudo-publicado-no-clinical-cancer-research-journal-destaca-o-uso-do-teste-endopredict-para-informar-o-tratamento-em-pacientes-com-cancer-de-mama-na-pre-menopausa\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/southafricahorizon.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo estudo publicado no Clinical Cancer Research Journal destaca o uso do teste EndoPredict para informar o tratamento em pacientes com c\u00e2ncer de mama na pr\u00e9-menopausa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/southafricahorizon.com\/#website\",\"url\":\"https:\/\/southafricahorizon.com\/\",\"name\":\"South Africa Horizon\",\"description\":\"A Horizon of Latest News Updates!\",\"publisher\":{\"@id\":\"https:\/\/southafricahorizon.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/southafricahorizon.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/southafricahorizon.com\/#organization\",\"name\":\"South Africa Horizon\",\"url\":\"https:\/\/southafricahorizon.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/southafricahorizon.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/southafricahorizon.com\/wp-content\/uploads\/2020\/06\/cropped-logo-sahorizon-op.png\",\"contentUrl\":\"https:\/\/southafricahorizon.com\/wp-content\/uploads\/2020\/06\/cropped-logo-sahorizon-op.png\",\"width\":300,\"height\":75,\"caption\":\"South Africa Horizon\"},\"image\":{\"@id\":\"https:\/\/southafricahorizon.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/southafricahorizon.com\/#\/schema\/person\/fdceae9c738422cfffedeec2ab0f5fdd\",\"name\":\"shadmin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/southafricahorizon.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"caption\":\"shadmin\"},\"url\":\"https:\/\/southafricahorizon.com\/author\/shadmin-s\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novo estudo publicado no Clinical Cancer Research Journal destaca o uso do teste EndoPredict para informar o tratamento em pacientes com c\u00e2ncer de mama na pr\u00e9-menopausa - South Africa Horizon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/southafricahorizon.com\/novo-estudo-publicado-no-clinical-cancer-research-journal-destaca-o-uso-do-teste-endopredict-para-informar-o-tratamento-em-pacientes-com-cancer-de-mama-na-pre-menopausa\/","og_locale":"en_US","og_type":"article","og_title":"Novo estudo publicado no Clinical Cancer Research Journal destaca o uso do teste EndoPredict para informar o tratamento em pacientes com c\u00e2ncer de mama na pr\u00e9-menopausa - South Africa Horizon","og_description":"O teste EndoPredict, da Myriad Genetics, identificou com precis\u00e3o mulheres na pr\u00e9-menopausa com c\u00e2ncer de mama ER+, HER2- que poderiam evitar, com seguran\u00e7a, a quimioterapia adjuvante SALT LAKE CITY, Aug. 31, 2022 (GLOBE NEWSWIRE) \u2014 A Myriad Genetics, Inc. \u00a0(NASDAQ: MYGN), l\u00edder em testes gen\u00e9ticos e medicina de precis\u00e3o, anunciou hoje que o Clinical Cancer [\u2026]","og_url":"https:\/\/southafricahorizon.com\/novo-estudo-publicado-no-clinical-cancer-research-journal-destaca-o-uso-do-teste-endopredict-para-informar-o-tratamento-em-pacientes-com-cancer-de-mama-na-pre-menopausa\/","og_site_name":"South Africa Horizon","article_published_time":"2022-08-31T12:11:10+00:00","author":"shadmin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"shadmin","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/southafricahorizon.com\/novo-estudo-publicado-no-clinical-cancer-research-journal-destaca-o-uso-do-teste-endopredict-para-informar-o-tratamento-em-pacientes-com-cancer-de-mama-na-pre-menopausa\/#article","isPartOf":{"@id":"https:\/\/southafricahorizon.com\/novo-estudo-publicado-no-clinical-cancer-research-journal-destaca-o-uso-do-teste-endopredict-para-informar-o-tratamento-em-pacientes-com-cancer-de-mama-na-pre-menopausa\/"},"author":{"name":"shadmin","@id":"https:\/\/southafricahorizon.com\/#\/schema\/person\/fdceae9c738422cfffedeec2ab0f5fdd"},"headline":"Novo estudo publicado no Clinical Cancer Research Journal destaca o uso do teste EndoPredict para informar o tratamento em pacientes com c\u00e2ncer de mama na pr\u00e9-menopausa","datePublished":"2022-08-31T12:11:10+00:00","dateModified":"2022-08-31T12:11:10+00:00","mainEntityOfPage":{"@id":"https:\/\/southafricahorizon.com\/novo-estudo-publicado-no-clinical-cancer-research-journal-destaca-o-uso-do-teste-endopredict-para-informar-o-tratamento-em-pacientes-com-cancer-de-mama-na-pre-menopausa\/"},"wordCount":1155,"publisher":{"@id":"https:\/\/southafricahorizon.com\/#organization"},"articleSection":["Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/southafricahorizon.com\/novo-estudo-publicado-no-clinical-cancer-research-journal-destaca-o-uso-do-teste-endopredict-para-informar-o-tratamento-em-pacientes-com-cancer-de-mama-na-pre-menopausa\/","url":"https:\/\/southafricahorizon.com\/novo-estudo-publicado-no-clinical-cancer-research-journal-destaca-o-uso-do-teste-endopredict-para-informar-o-tratamento-em-pacientes-com-cancer-de-mama-na-pre-menopausa\/","name":"Novo estudo publicado no Clinical Cancer Research Journal destaca o uso do teste EndoPredict para informar o tratamento em pacientes com c\u00e2ncer de mama na pr\u00e9-menopausa - South Africa Horizon","isPartOf":{"@id":"https:\/\/southafricahorizon.com\/#website"},"datePublished":"2022-08-31T12:11:10+00:00","dateModified":"2022-08-31T12:11:10+00:00","breadcrumb":{"@id":"https:\/\/southafricahorizon.com\/novo-estudo-publicado-no-clinical-cancer-research-journal-destaca-o-uso-do-teste-endopredict-para-informar-o-tratamento-em-pacientes-com-cancer-de-mama-na-pre-menopausa\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/southafricahorizon.com\/novo-estudo-publicado-no-clinical-cancer-research-journal-destaca-o-uso-do-teste-endopredict-para-informar-o-tratamento-em-pacientes-com-cancer-de-mama-na-pre-menopausa\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/southafricahorizon.com\/novo-estudo-publicado-no-clinical-cancer-research-journal-destaca-o-uso-do-teste-endopredict-para-informar-o-tratamento-em-pacientes-com-cancer-de-mama-na-pre-menopausa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/southafricahorizon.com\/"},{"@type":"ListItem","position":2,"name":"Novo estudo publicado no Clinical Cancer Research Journal destaca o uso do teste EndoPredict para informar o tratamento em pacientes com c\u00e2ncer de mama na pr\u00e9-menopausa"}]},{"@type":"WebSite","@id":"https:\/\/southafricahorizon.com\/#website","url":"https:\/\/southafricahorizon.com\/","name":"South Africa Horizon","description":"A Horizon of Latest News Updates!","publisher":{"@id":"https:\/\/southafricahorizon.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/southafricahorizon.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/southafricahorizon.com\/#organization","name":"South Africa Horizon","url":"https:\/\/southafricahorizon.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/southafricahorizon.com\/#\/schema\/logo\/image\/","url":"https:\/\/southafricahorizon.com\/wp-content\/uploads\/2020\/06\/cropped-logo-sahorizon-op.png","contentUrl":"https:\/\/southafricahorizon.com\/wp-content\/uploads\/2020\/06\/cropped-logo-sahorizon-op.png","width":300,"height":75,"caption":"South Africa Horizon"},"image":{"@id":"https:\/\/southafricahorizon.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/southafricahorizon.com\/#\/schema\/person\/fdceae9c738422cfffedeec2ab0f5fdd","name":"shadmin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/southafricahorizon.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","caption":"shadmin"},"url":"https:\/\/southafricahorizon.com\/author\/shadmin-s\/"}]}},"_links":{"self":[{"href":"https:\/\/southafricahorizon.com\/wp-json\/wp\/v2\/posts\/46530"}],"collection":[{"href":"https:\/\/southafricahorizon.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/southafricahorizon.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/southafricahorizon.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/southafricahorizon.com\/wp-json\/wp\/v2\/comments?post=46530"}],"version-history":[{"count":1,"href":"https:\/\/southafricahorizon.com\/wp-json\/wp\/v2\/posts\/46530\/revisions"}],"predecessor-version":[{"id":46531,"href":"https:\/\/southafricahorizon.com\/wp-json\/wp\/v2\/posts\/46530\/revisions\/46531"}],"wp:attachment":[{"href":"https:\/\/southafricahorizon.com\/wp-json\/wp\/v2\/media?parent=46530"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/southafricahorizon.com\/wp-json\/wp\/v2\/categories?post=46530"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/southafricahorizon.com\/wp-json\/wp\/v2\/tags?post=46530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}